FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:843-844 March 15, 2001 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by West, L. J. PubMed Citation

Cardiac transplantation has now been performed for 15 years as therapy for neonates and infants with lethal myopathic or structural heart disease. Such transplantation has been stimulated by both the needs of the infants and the promise of an immunologic window of opportunity for safe transplantation, owing to the immaturity of infants' immune systems. The first series of three infants with hypoplastic left heart syndrome who underwent orthotopic heart transplantation was reported by Bailey and colleagues in 1986.¹ Subsequently, infants have accounted for approximately 40 percent of all heart transplantations in children. However, the number of such procedures in children, . . . [Full Text of this Article]

References

This article has been cited by other articles:

• West, L. J., Karamlou, T., Dipchand, A. I., Pollock-BarZiv, S. M., Coles, J. G., McCrindle, B. W. (2006). Impact on outcomes after listing and transplantation, of a strategy to accept ABO blood group-incompatible donor hearts for neonates and infants. J. Thorac. Cardiovasc. Surg. 131: 455-461 [Abstract] [Full Text]  
• Azeka, E., Franchini Ramires, J. A., Valler, C., Alcides Bocchi, E. (2002). Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol 40: 2034-2038 [Abstract] [Full Text]